Epoetins: Differences and their relevance to immunogenicity

Current Medical Research and Opinion

Volumn 19, Issue 5, 2003, Pages 430-432

  Haselbeck, Anton ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Epoetin alfa; Epoetin beta; Immunogenicity; Pure red cell aplasia

Indexed keywords

GLYCINE; HUMAN SERUM ALBUMIN; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN; STABILIZING AGENT;

ARTICLE; CHEMICAL MODIFICATION; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; HUMAN; IMMUNOGENICITY; INCIDENCE; MATERIALS HANDLING; PROTEIN STABILITY; PURE RED CELL ANEMIA;

EID: 0042510222     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002063     Document Type: Article

References (18)

1. Casadevall N, Mayeux P. N Engl J Med 2002;346:1585 (correction: N Engl J Med 2002;347:458)
2. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346:1584-6
3. Ortho Biotech. Dear Healthcare Professional letter, 17 July 2002
4. Johnson & Johnson. Press release. 24 March 2003 (http://www.jnj.com/news/jnj news/1021024 095632.htm)
5. Epogen® product information. Amgen Inc, USA. (http://www.renal-advances.com/resources/products/epogenpi.html)
6. Procrit® product information. Ortho Biotech Products, L.P., USA. (http://healthcareprofessionals.orthobiotech.com/products/procrit.jsp)
7. Eprex® Summary of Product Characteristics. Janssen Cilag Ltd, UK. Issued 17 July 2002 (http://www.janssen-cilag.com.eg/pdf/prof/eprexprof.pdf
8. NeoRecormon® Summary of Product Characteristics. Roche Registration Ltd, UK. Issued August 2002 (http://www.rocheuk.com/html/health/KidneyDiseaseProducts.asp?Prodlink=112)
9. Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89
10. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-12
11. Bunn HF. Drug-induced autoimmune red-cell aplasia. N Engl J Med 2002;346:522-3
12. Levin A, Barrett BJ, Wong G, Singer J, McMahon L. Letter from the Canadian Society of Nephrology. Issued 15 August 2002 (http://csnscn.ca/)
13. Health Sciences Authority (Singapore). Epoetin alfa (Eprex®) & pure red cell aplasia (PRCA). Drug Safety Information No. 5. Issued 27 August 2002
14. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003;18:865-9
15. French Health Authority letter. Issued 2 December 2002 (http://afssaps.sante.fr/htm/3/3000.htm)
16. Eprex® Summary of Product Characteristics. Janssen Cilag Ltd, UK. Issued 17 July 2002 (http://www.janssen-cilag.com.eg/pdf/prof/eprexprof.pdf)
17. Ahmed MO. Comparison of impact of different hydrophilic carriers on the properties of piperazine-containing drug. Eur J Pharm Biopharm 2001;51:221-5
18. Johnson & Johnson news website (http://www.jnj.com/news/jnj news/)